【AI Explained】Nanotechnology and immunoengineering: How nanotechnology can boost CAR-T therapy.

Literature Information

TL;DR

This review discusses the integration of nanotechnology into chimeric antigen receptor (CAR) T-cell therapy to address the challenges associated with its complex manufacturing and limited efficacy in solid tumors. By presenting strategies for using nanoparticles as carriers to enhance CAR-T therapy, the paper highlights the potential of nanotechnology to improve treatment outcomes and broaden the application of CAR-T therapy in oncology.

Search for more papers on MaltSci.com

Chimeric antigen receptor · Immune cells · Immunoengineering · Intracellular transport · Nano-immunotherapeutics

Abstract

Chimeric antigen receptor (CAR) therapy has achieved remarkable clinical efficacy against hematological cancers and has been approved by FDA for treatment of B-cell tumors. However, the complex manufacturing process and limited success in solid tumors hamper its widespread applications, thus prompting the development of new strategies for overcoming the abovementioned hurdles. In the last decade, nanotechnology has provided sustainable strategies for improving cancer immunotherapy through vaccine development and delivery of immunomodulatory drugs. Nanotechnology can boost CAR-T therapy and may overcome the existing challenges by emerging as a carrier for CAR-T therapy or in combination with CAR-T, it may inhibit solid tumors more effectively than conventional approaches. The revealing of cellular mechanisms, barriers and potential strategies that could be used to manipulate and/or modify cells would enable unprecedented advances in nanotechnology for biologics delivery. This review outlines the journey and barriers of nanoparticles (NPs) across the cell. Subsequently, the approaches to tackle the barriers and strategies to modulate NPs as a carrier for CAR-T therapy are discussed. Finally, the role of NPs in CAR-T therapy and the potential challenges are summarized. This review aims to provide the readers with a detailed overview of NP-based CAR-T therapy research and distil this information into an accessible form conducive to design desired CAR-T therapy using NP approach. STATEMENT OF SIGNIFICANCE: Chimeric antigen receptor (CAR) T-cell therapy is the most vibrant field in immuno-oncology today, with enormous benefits to patients with B-cell malignancies. However, a rapid and straightforward procedure for CAR-T generation is an exigent need to broaden its therapeutic avenue. Nanotechnology has emerged as a novel alternative approach for CAR-T generation. To the best of our knowledge, this is the first in-depth review that briefly highlights the various aspects of nanotechnology in CAR-T therapy, including the strategies to brand NPs as an effective carrier for CAR cargo, its potential advantages, challenges, and future roadmap. It provides readers with a detailed overview of NP-based CAR-T therapy research, and researchers would be able to distill this information into an accessible form conducive to design the desired CAR therapy using the nanotechnology approach.

MaltSci.com AI Research Service

Primary Questions Addressed

1. What specific types of nanoparticles are most effective in enhancing CAR-T therapy, and why?
2. How do the cellular mechanisms involved in nanoparticle delivery impact the efficacy of CAR-T therapy?
3. What are the current limitations of using nanotechnology in CAR-T therapy, and how can they be addressed?
4. In what ways can the combination of nanotechnology and CAR-T therapy improve outcomes for solid tumors compared to hematological cancers?
5. What future research directions are necessary to optimize the use of nanotechnology in CAR-T therapy development?

Key Findings

Key Insights

1. Research Background and Objectives: Chimeric Antigen Receptor (CAR) therapy has shown significant success in treating hematological cancers, particularly B-cell tumors, leading to FDA approval for clinical use. However, challenges remain, particularly in the complex manufacturing processes of CAR-T cells and their limited effectiveness against solid tumors. This research explores the integration of nanotechnology into CAR-T therapy as a means to enhance its efficacy and accessibility, aiming to provide sustainable solutions to existing barriers and broaden the therapeutic applications of CAR-T cells.

2. Major Methods and Findings: The review discusses the role of nanoparticles (NPs) in advancing CAR-T therapy, focusing on their potential as carriers for CAR therapies and their ability to improve the delivery of immunomodulatory drugs. It details the cellular mechanisms that NPs encounter when traversing biological barriers and the strategies that can be employed to optimize NP design for effective CAR-T cell delivery. Key findings indicate that NPs can enhance the targeting and penetration of CAR-T cells into solid tumors, potentially overcoming traditional limitations associated with CAR-T therapies.

3. Core Conclusions: Nanotechnology presents a novel and promising approach to improving CAR-T therapy. By utilizing NPs as carriers, the review suggests that it is possible to modulate and enhance the performance of CAR-T cells, making them more effective against solid tumors. This integration of nanotechnology not only addresses the manufacturing complexities but also provides a platform for innovative drug delivery systems that can be tailored for specific therapeutic needs. The review underscores the necessity for further research into NP design and optimization to fully realize the potential of this combined approach.

4. Research Significance and Impact: This review is significant as it provides a comprehensive overview of the intersection between nanotechnology and CAR-T therapy, highlighting the transformative potential of NPs in immuno-oncology. It emphasizes the urgent need for streamlined CAR-T generation processes, which could expand treatment options for a broader range of cancers. By distilling complex information into accessible insights, the review supports researchers in the field to design and implement NP-based CAR-T therapies effectively. Ultimately, this work could lead to improved patient outcomes, particularly for those suffering from solid tumors, thus significantly impacting the future landscape of cancer immunotherapy.

Literatures Citing This Work

1. Modulating barriers of tumor microenvironment through nanocarrier systems for improved cancer immunotherapy: a review of current status and future perspective. - Huanrong Lan;Wei Zhang;Ketao Jin;Yuyao Liu;Zhen Wang - Drug delivery (2020)
2. Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy. - Wei Li;Anghui Peng;Huajun Wu;Yingyao Quan;Yong Li;Ligong Lu;Min Cui - Frontiers in immunology (2020)
3. Nanomedicine-based cancer immunotherapy: recent trends and future perspectives. - Vinoth-Kumar Lakshmanan;Shlok Jindal;Gopinath Packirisamy;Shreesh Ojha;Sen Lian;Ajeet Kaushik;Abdulqadir Ismail M Abdullah Alzarooni;Yasser Abdelraouf Farahat Metwally;Sadras Panchatcharam Thyagarajan;Young Do Jung;Salem Chouaib - Cancer gene therapy (2021)
4. Nanomaterials for Biomedical Applications: Production, Characterisations, Recent Trends and Difficulties. - Mostafa Mabrouk;Diganta B Das;Zeinab A Salem;Hanan H Beherei - Molecules (Basel, Switzerland) (2021)
5. Nanoparticles for Enhanced Adoptive T Cell Therapies and Future Perspectives for CNS Tumors. - Preethi Bala Balakrishnan;Elizabeth E Sweeney - Frontiers in immunology (2021)
6. Cancer immunotherapies revisited: state of the art of conventional treatments and next-generation nanomedicines. - Coral García-Fernández;Anna Saz;Cristina Fornaguera;Salvador Borrós - Cancer gene therapy (2021)
7. In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy. - Tianqing Xin;Li Cheng;Chuchao Zhou;Yimeng Zhao;Zhenhua Hu;Xiaoyan Wu - Frontiers in oncology (2022)
8. Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy. - Seungyong Shin;Pyunghwajun Lee;Jieun Han;Se-Na Kim;Jaesung Lim;Dae-Hwan Park;Taejong Paik;Junhong Min;Chun Gwon Park;Wooram Park - Tissue engineering and regenerative medicine (2023)
9. Self-assembled nanoparticles: A new platform for revolutionizing therapeutic cancer vaccines. - Tianyu Shi;Mengna Sun;Changchang Lu;Fanyan Meng - Frontiers in immunology (2023)
10. Theranostic applications of selenium nanomedicines against lung cancer. - Shaowei Liu;Weifeng Wei;Jinlin Wang;Tianfeng Chen - Journal of nanobiotechnology (2023)

… (22 more literatures)

© 2025 MaltSci - We reshape scientific research with AI technology